Metastatic Colorectal Cancer Clinical Trials

A listing of 21 Metastatic Colorectal Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Colorectal Cancer

1 - 12 of 21

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 21 active clinical trials seeking participants for Metastatic Colorectal Cancer research studies. The states with the highest number of trials for Metastatic Colorectal Cancer participants are California, Florida, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121

Recruiting

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause digestive tract, urothelial, breast, or ovarian/endometrial tumors to shrink and to see if this treatment is safe. Eligibility: - Adults age 18-72 with upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial cancer, or glioblastoma refractory to standard chemotherapy. Design: Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed. Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. (Leukapheresis is a common procedure, which removes only the white blood cells from the patient.) Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days. ... Read Less

Gender:

ALL

Ages:

Between 18 years and 72 years

Trial Updated:

03/21/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors

Learn More ›

A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer

NCT06614192

Recruiting

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put int... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/19/2025

Locations: City of Hope National Medical Center /ID# 267875, Duarte, California +46 locations

City of Hope National Medical Center /ID# 267875, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center /ID# 270655, Irvine, California

USC Norris Comprehensive Cancer Center /ID# 268131, Los Angeles, California

Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175, Golden, Colorado

Yale New Haven Hospital /ID# 269125, New Haven, Connecticut

AdventHealth Orlando /ID# 267970, Orlando, Florida

St. Luke's Cancer Institute: Boise /ID# 268095, Boise, Idaho

Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 268610, Chicago, Illinois

Hope And Healing Cancer Services /ID# 268541, Hinsdale, Illinois

Springfield Clinic /ID# 268666, Springfield, Illinois

Community Cancer Center North /ID# 267965, Indianapolis, Indiana

Hattiesburg Clinic /ID# 267860, Hattiesburg, Mississippi

Washington University /ID# 267872, Saint Louis, Missouri

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 268185, Billings, Montana

Rutgers Cancer Institute of New Jersey /ID# 268056, New Brunswick, New Jersey

Duke University Medical Center /ID# 267966, Durham, North Carolina

Avera Cancer Institute - Sioux Falls /ID# 268074, Sioux Falls, South Dakota

West Cancer Center and Research Institute - Germantown /ID# 268619, Germantown, Tennessee

The University of Texas MD Anderson Cancer Center /ID# 268098, Houston, Texas

Millennium Research & Clinical Development /ID# 268400, Houston, Texas

University of Virginia /ID# 268108, Charlottesville, Virginia

Mater Hospital Brisbane /ID# 268360, South Brisbane, Queensland

Rambam Health Care Campus /ID# 267739, Haifa, H_efa

The Chaim Sheba Medical Center /ID# 267741, Ramat Gan, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 267578, Tel Aviv, Tel-Aviv

Hadassah Medical Center-Hebrew University /ID# 267579, Jerusalem, Not set

Rabin Medical Center /ID# 267740, Petah Tikva, Not set

Assuta Medical Center /ID# 267745, Tel Aviv, Not set

National Cancer Center Hospital East /ID# 268236, Kashiwa-shi, Chiba

Osaka University Hospital /ID# 268743, Suita-shi, Osaka

Saitama Cancer Center /ID# 268706, Kitaadachi-gun, Saitama

National Cancer Center Hospital /ID# 268713, Chuo-Ku, Tokyo

Seoul National University Bundang Hospital /ID# 268592, Seongnam-si, Gyeonggido

Seoul National University Hospital /ID# 268719, Seoul, Seoul Teugbyeolsi

Yonsei University Health System Severance Hospital /ID# 268718, Seoul, Seoul Teugbyeolsi

Asan Medical Center /ID# 268717, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 268720, Seoul, Seoul Teugbyeolsi

Pan American Center for Oncology Trials /ID# 267888, Rio Piedras, Not set

Kaohsiung Chang Gung Memorial Hospital /ID# 267638, Kaohsiung City, Kaohsiung

National Taiwan University Hospital /ID# 267627, Taipei City, Taipei

Changhua Christian Hospital /ID# 270464, Changhua City, Changhua County, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267635, Kaohsiung, Not set

China Medical University Hospital /ID# 267631, Taichung, Not set

Taichung Veterans General Hospital /ID# 270467, Taichung, Not set

National Cheng Kung University Hospital /ID# 270468, Tainan, Not set

Taipei Veterans General Hospital /ID# 267628, Taipei City, Not set

Linkou Chang Gung Memorial Hospital /ID# 267637, Taoyuan City, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695

Recruiting

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

03/19/2025

Locations: Research Site, Scottsdale, Arizona +58 locations

Research Site, Scottsdale, Arizona

Research Site, Los Angeles, California

Research Site, Washington, District of Columbia

Research Site, Chicago, Illinois

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Rochester, Minnesota

Research Site, Rochester, New York

Research Site, Cleveland, Ohio

Research Site, Houston, Texas

Research Site, East Melbourne, Not set

Research Site, Wollongong, Not set

Research Site, Victoria, British Columbia

Research Site, Barrie, Ontario

Research Site, Toronto, Ontario

Research Site, Montreal, Quebec

Research Site, Beijing, Not set

Research Site, Harbin, Not set

Research Site, Shanghai, Not set

Research Site, Zhengzhou City, Not set

Research Site, Bordeaux, Not set

Research Site, Montpellier, Not set

Research Site, Poitiers, Not set

Research Site, Saint-Priez En Jarez, Not set

Research Site, Villejuif Cedex, Not set

Research Site, Berlin, Not set

Research Site, Dresden, Not set

Research Site, Essen, Not set

Research Site, Hamburg, Not set

Research Site, Marburg, Not set

Research Site, Firenze, Not set

Research Site, Milano, Not set

Research Site, Napoli, Not set

Research Site, Pavia, Not set

Research Site, Roma, Not set

Research Site, Seoul, Not set

Research Site, Yongin-si, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Malaga, Not set

Research Site, Pamplona, Not set

Research Site, Santander, Not set

Research Site, València, Not set

Research Site, Kaohsiung, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Yung Kang City, Not set

Research Site, Cambridge, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Wirral, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463

Recruiting

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/19/2025

Locations: Hope And Healing Cancer Services /ID# 271562, Hinsdale, Illinois +2 locations

Conditions: Metastatic Colorectal Cancer

Learn More ›

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481

Recruiting

Background: Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and spread to other organs. This is called metastatic colorectal cancer (mCRC). Most people with mCRC survive only about 2 years. Objective: To test the ability of a combination of up to 4 experimental anti-cancer drugs treat mCRC. The names of these drugs are retifanlimab, TriAdeno vaccine, N-803, and SX-682. They are described below. Eligi... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

03/14/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223

Recruiting

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +72 locations

UAB Comprehensive Cancer Center, Birmingham, Alabama

Mayo Clinic Arizona, Phoenix, Arizona

City of Hope Comprehensive Cancer Center, Duarte, California

cCare, Encinitas, California

USC Norris Cancer Center, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Stanford Cancer Center, Stanford, California

University of Colorado Cancer Center, Aurora, Colorado

Yale Cancer Center, New Haven, Connecticut

Eastern Ct Hema/Onco Assoc, Norwich, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

Moffitt Cancer Center, Tampa, Florida

Mary Bird Perkins Cancer Ctr, Baton Rouge, Louisiana

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

New York Cancer & Blood Specialists - Bronx, Bronx, New York

New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park, New York

New York Cancer and Blood Specialists-Central Park Hematology & Oncology, New York, New York

New York Cancer & Blood Specialists, Port Jefferson Station, New York

Duke University Medical Center, Durham, North Carolina

Hematology Oncology Salem, Salem, Oregon

UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Lumi Research, Kingwood, Texas

Swedish Cancer Inst., Seattle, Washington

Medical Oncology Associates, Spokane, Washington

Peter Maccallum Cancer Centre, Melbourne, Victoria

Princess Margaret Cancer Center, Toronto, Ontario

Jewish General Hospital, Montreal, Quebec

McGill University Health Center, Montreal, Quebec

Rigshospitalet, Onkologisk Klinik, København Ø, Not set

Charité Universitätsmedizin Berlin, Berlin, Not set

Katholisches Klinikum Bochum gGmbH - St. Josef-Hospital, Bochum, Not set

Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Dresden, Not set

Universitätsklinikum Düsseldorf, Düsseldorf, Not set

Asklepios Klinik Altona, Hamburg, Not set

SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III, Heilbronn, Not set

Klinikum der Universität München, Campus Großhadern, München, Not set

Universitätsklinikum Ulm, Ulm, Not set

Università degli Studi della Campania Luigi Vanvitelli, Napoli, Campania

Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio

Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia

Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia

IRCCS Istituto Oncologico Veneto (IOV), Padova, Veneto

National Cancer Center, Goyang-si, Not set

Chonnam National University Hwasun Hospital, Jeollanam-do, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Kraków, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Not set

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie, Warszawa, Not set

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Not set

START Madrid. Centro Integral Oncologico Clara Campal, Madrid, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei City, Not set

National Taiwan University Hospital, Zhongzheng Dist., Not set

Addenbrookes Hospital, Cambridge, Not set

Velindre Cancer Centre, Cardiff, Not set

Royal Free Hospital, London, Not set

Royal Marsden Hospital;Dept of Med-Onc, London, Not set

Sarah Cannon Research Institute, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

NCT05382442

Recruiting

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

03/07/2025

Locations: Summit Therapeutics Research Site, Los Angeles, California +1 locations

Conditions: Metastatic Colorectal Cancer

Learn More ›

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649

Recruiting

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona +122 locations

Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona

Providence Saint Jude Medical Center, Fullerton, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

Norwalk Hospital, Norwalk, Connecticut

Cancer Specialists of North Florida, Jacksonville, Florida

D and H Cancer Research Center, Margate, Florida

Mid Florida Hematology and Oncology Centers PA, Orange City, Florida

Boca Raton Clinical Research Medical Center Inc, Plantation, Florida

Georgia Cancer Specialists, Atlanta, Georgia

Hope and Healing Cancer Services, Hinsdale, Illinois

Orchard Healthcare Research Inc, Skokie, Illinois

Pikeville Medical Center, Pikeville, Kentucky

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan

Saint Louis Cancer Care West County, Bridgeton, Missouri

Minniti Center for Medical Oncology and Hematology, Mickleton, New Jersey

Duke Cancer Center, Durham, North Carolina

FirstHealth Cancer Center, Pinehurst, North Carolina

Thomas Jefferson University, Philadelphia, Pennsylvania

Carolina Blood and Cancer Care, Rock Hill, South Carolina

Hospital Universitario Fundacion Favaloro, Caba, Buenos Aires

Instituto Argentino de Diagnóstico y Tratamiento, Caba, Buenos Aires

Cemic, Ciudad Autonoma de Buenos Aires, Buenos Aires

Sanatorio Británico de Rosario, La Plata, Buenos Aires

Instituto de Investigaciones clinicas de Mar del Plata, Mar Del Plata, Buenos Aires

Sanatorio Allende, Cordoba, Córdoba

Clinica Universitaria Privada Reina Fabiola, Cordoba, Córdoba

Clinica Viedma, Viedma, Río Negro

Exelsus Oncologia Clinica, San Miguel de Tucuman, Tucuman

Hospital Britanico de Buenos Aires, Buenos Aires, Not set

Centro Oncologico Riojano Integral, La Rioja, Not set

Chris OBrien Lifehouse, Camperdown, New South Wales

Toowoomba Hospital, Toowoomba, Queensland

Flinders Medical Centre, Bedford Park, South Australia

The Queen Elizabeth Hospital, Woodville South, South Australia

Austin Health, Austin Hospital, Heidelberg, Victoria

Landeskrankenhaus Feldkirch, Rankweil, Not set

Hospital Sirio Libanes, Brasilia, Distrito Federal

Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Espírito Santo

Vencer e Oncoclinica, Teresina, Piauí

Liga Norte-Riograndense Contra O Cancer, Natal, Rio Grande Do Norte

Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul

Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul

Associação Hospitalar Moinhos de Vento, Porto Alegre, Rio Grande Do Sul

Clinica de Neoplasias Litoral, Itajai, Santa Catarina

Fundacao Pio 12 Hospital de Amor de Barretos, Barretos, São Paulo

Oncoclinicas Belo Horizonte, Barretos, São Paulo

Fundacao Antonio Prudente AC Camargo Cancer Center, Sao Paulo, São Paulo

Oncologia Rede D Or, Sao Paulo, São Paulo

Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo

Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, Not set

Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp, São Paulo, Not set

Instituto Brasileiro de Controle do Cancer Ibcc, São Paulo, Not set

Specialized Hospital for Active Treatment of Oncology - Haskovo EOOD, Haskovo, Not set

Multiprofile Hospital for Active Treatment Central Onco Hospital OOD, Plovdiv, Not set

Complex Oncology Center Plovdiv EOOD, Plovdiv, Not set

Multiprofile Hospital for Active Treatment Serdika EOOD, Sofia, Not set

Centro de oncologia de precision Spa, Las Condes, Santiago

Institucion Prestadora de Servicios de Salud Sociedad Médica Rionegro SA Somer SA, Rionegro, Antioquia

Instituto Nacional de Cancerologia, Bogota, Cundinamarca

Centro de Tratamiento e Investigación sobre Cancer Luis Carlos Sarmiento Angulo Ctic, Bogotá, Cundinamarca

Oncomedica SAS, Montería, Córdoba

Fundacion Oftalmologica de Santander - Foscal, Floridablanca, Santander

Fakultni nemocnice v Motole, Praha 5, Not set

Aarhus University Hospital, Aarhus N, Not set

Rigshospitalet, Copenhagen, Not set

North Estonia Medical Centre Foundation, Tallinn, Not set

Universitaetsklinikum Dresden, Dresden, Not set

UCT Universitaeres Zentrum fuer Tumorerkrankungen Frankfurt, Frankfurt am Main, Not set

Haematologisch Onkologische Praxis Eppendorf, Hamburg, Not set

Regional Kliniken Holding Klinikum Ludwigsburg, Ludwigsburg, Not set

Klinikum der LMU Muenchen, Muenchen, Not set

Klinikum der Stadt Wolfsburg, Wolfsburg, Not set

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Princess Margaret Hospital, Kowloon, Not set

Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz, Gyula, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

Chiba Cancer Center, Chiba-shi, Chiba

National Cancer Center Hospital East, Kashiwa-shi, Chiba

National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime

National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka

Hokkaido University Hospital, Sapporo, Hokkaido

Hyogo Cancer Center, Akashi-shi, Hyogo

St Marianna University Hospital, Kawasaki-shi, Kanagawa

Yokohama City University Medical Center, Yokohama-shi, Kanagawa

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa

Niigata Cancer Center Hospital, Niigata-shi, Niigata

Kansai Medical University Hospital, Hirakata-shi, Osaka

National Hospital Organization Osaka National Hospital, Osaka-shi, Osaka

Osaka University Hospital, Suita-shi, Osaka

Saitama Cancer Center, Kitaadachi-gun, Saitama

Shizuoka Cancer Center, Sunto-gun, Shizuoka

Tokushima University Hospital, Tokushima-shi, Tokushima

National Cancer Center Hospital, Chuo-ku, Tokyo

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

National Cancer Center, Goyang-si Gyeonggi-do, Not set

Korea University Anam Hospital, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Hospital Universitario Reina Sofia, Cordoba, Andalucía

Hospital Universitario Virgen de las Nieves, Granada, Andalucía

Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Universitaetsspital Zuerich, Zuerich, Not set

China Medical University Hospital, Taichung, Not set

Taichung Veterans General Hospital, Taichung, Not set

Taipei Veterans General Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Not set

Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Not set

Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Not set

Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi, Ankara, Not set

Ankara Bilkent Sehir Hastanesi, Ankara, Not set

Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi, Edirne, Not set

Bezmialem Vakif Universitesi Hastanesi, Istanbul, Not set

Bagcilar Medipol Mega Universite Hastanesi, Istanbul, Not set

Acibadem Altunizade Hastanesi, Istanbul, Not set

Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Not set

Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi, Konya, Not set

Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)

NCT06625775

Recruiting

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/25/2025

Locations: University of California Los Angeles, Los Angeles, California +6 locations

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, HER2-Positive Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer

Learn More ›

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

NCT06412198

Recruiting

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/13/2025

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations

Conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations

Learn More ›

Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064

Recruiting

RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to ant... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/10/2025

Locations: University of California, Los Angeles, Los Angeles, California +2 locations

Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer

Learn More ›

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

Recruiting

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2025

Locations: Highlands Oncology Group, Springdale, Arkansas +36 locations

Highlands Oncology Group, Springdale, Arkansas

University of California at Davis, Davis, California

The Oncology Institute of Hope and Innovation, Downey, California

City of Hope Cancer Center, Duarte, California

University of Colorado Hospital, Aurora, Colorado

Nuvance Health, Norwalk, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

Florida Cancer Specialists, Atlantis, Florida

University of Florida Health Cancer Center, Gainesville, Florida

Ocala Oncology Florida Cancer Affiliates, Ocala, Florida

AdventHealth Cancer Institute, Orlando, Florida

Memorial Cancer Institute, Pembroke Pines, Florida

Emory University Winship Cancer Institute, Atlanta, Georgia

Norton Health, Lexington, Kentucky

Greater Baltimore Medical Center, Baltimore, Maryland

The Center for Cancer and Blood Disorders, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan Medical Center, Ann Arbor, Michigan

Atlantic Healthcare System, Morristown, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

The Ohio State University James Cancer Center, Columbus, Ohio

Zangmeister Cancer Center, Columbus, Ohio

Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center), Gettysburg, Pennsylvania

Prisma Health, Greenville, South Carolina

Tennessee Oncology Chattanooga Memorial Plaza, Chattanooga, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Houston Methodist Cancer Center, Houston, Texas

Oncology Consultants, Houston, Texas

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

NEXT/Virginia Cancer Specialists, Fairfax, Virginia

University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington

Newcastle Private Hospital, New Lambton Heights, New South Wales

Tasman Oncology Research, Southport, Queensland

Cancer Research SA, Adelaide, South Australia

Southern Oncology Clinical Research Unit, Bedford Park, South Australia

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

Learn More ›

1 - 12 of 21